Combine 6-8 suppliers into one and simplify life for your study operations teams.
Corrective and Preventive Actions (CAPAs) are intended to strengthen quality in clinical trials, but too often they become paperwork rather than prevention. What’s missing is the system-level work that actually reduces recurrence. If you’re shaping CAPA processes or strengthening risk management in your organization, this piece offers a clear, practical framework.
In today’s clinical research environment, ESG performance is increasingly considered when sponsors and CROs evaluate operational partners and service providers. Our blog post explores how sustainability and ESG expectations are shaping partnerships across the clinical research industry.
Clinical trials are stronger when intelligence is shared rather than siloed. At the SCOPE summit, the recurring theme was collective intelligence. When sponsors, CROs, sites, technology partners, and participants are truly connected, decisions improve, risks are easier to anticipate, and studies become more resilient. Explore our blog to discover how this approach is shaping the future of clinical trials.